Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for four medicines.
- Tirbanibulin (Klisyri®) is recommended as an option for treating mild actinic keratosis – a rough area of skin that has developed in people who have been exposed to too much sunshine over a long time. Tirbanibulin should only be used for flat actinic keratosis on the face and scalp in adults.
- Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is recommended for use in children, aged two years or older, with cerebral palsy, to treat muscle spasms in the arms.
- Ravulizumab (Ultomiris®) is recommended as an option to treat a disease called paroxysmal nocturnal haemoglobulinaemia (PNH) in children and young people who weigh at least 10 kg or more. This includes patients untreated with complement inhibitor and patients who have received eculizumab for at least the past 6 months. PNH is a rare blood condition in which part of the immune system is overactive and attacks red blood cells.
- Inclisiran (Leqvio®) is recommended as an option for use to lower cholesterol levels in adults at high cardiovascular risk for whom standard medications have not lowered their cholesterol levels enough. Inclisiran is given by injection every six months, and may provide a convenient option for some patients to manage their condition.
- Buprenorphine (Sixmo®) is not recommended to treat opioid dependence in adults who are also receiving medical, social and psychological support. Sixmo® contains the active substance buprenorphine, which is a type of opioid medicine. It is implanted into the upper arm to deliver six months of treatment.
AWTTC supports AWMSG to assess and monitor new medicines in Wales.